FY2030 Earnings Forecast for Absci Issued By HC Wainwright

Posted by Geri Gentry on May 12th, 2026

Absci Corporation (NASDAQ:ABSI – Free Report) – Investment analysts at HC Wainwright lifted their FY2030 EPS estimates for Absci in a research note issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.64 per share for the year, up from their previous forecast of $0.61. The consensus estimate for Absci’s current full-year earnings is ($0.83) per share.

A number of other research firms also recently weighed in on ABSI. Weiss Ratings reissued a “sell (d-)” rating on shares of Absci in a report on Monday, April 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Absci in a report on Wednesday, March 25th. Finally, Truist Financial lifted their price target on shares of Absci from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.58.

Get Our Latest Stock Analysis on ABSI

Absci Price Performance

ABSI stock opened at $5.78 on Tuesday. Absci has a 1 year low of $2.24 and a 1 year high of $6.72. The company has a market cap of $901.10 million, a P/E ratio of -6.96 and a beta of 2.36. The stock’s fifty day moving average price is $3.41 and its 200-day moving average price is $3.33.

Absci (NASDAQ:ABSI – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The business had revenue of $0.22 million during the quarter, compared to the consensus estimate of $1.39 million. Absci had a negative net margin of 6,450.76% and a negative return on equity of 66.32%.

Insider Transactions at Absci

In other news, insider Andreas Busch bought 100,000 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were bought at an average price of $2.29 per share, for a total transaction of $229,000.00. Following the purchase, the insider owned 421,446 shares in the company, valued at approximately $965,111.34. The trade was a 31.11% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.49% of the company’s stock.

Institutional Trading of Absci

Hedge funds and other institutional investors have recently modified their holdings of the company. ARK Investment Management LLC boosted its holdings in Absci by 21.1% in the 3rd quarter. ARK Investment Management LLC now owns 12,162,773 shares of the company’s stock worth $36,975,000 after buying an additional 2,116,845 shares during the period. Heights Capital Management Inc. purchased a new stake in Absci in the 3rd quarter worth $6,081,000. Orion Porfolio Solutions LLC bought a new stake in Absci during the third quarter valued at about $36,000. Scientech Research LLC bought a new stake in Absci during the third quarter valued at about $31,000. Finally, Quarry LP purchased a new position in shares of Absci in the third quarter valued at about $26,000. 52.05% of the stock is owned by hedge funds and other institutional investors.

Absci Company Profile

(Get Free Report)

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.